Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being
tested in ovarian cancer patients. Immunotherapy causes the body's defenses to react against
cancer cells. The purpose of this research study is to determine if immunotherapy with
oregovomab can create an immune response and enable the body to fight the disease and help
ovarian cancer patients live longer. Patients with a possible diagnosis of ovarian cancer
will be screened for study participation pre-surgery and, if eligible, will receive
oregovomab during front-line chemotherapy treatment for ovarian cancer and quarterly for
about a year following chemotherapy. Patients who experience disease progression will be
discontinued from oregovomab therapy. Patients will also have urine, blood and tissue samples
collected to assess the immune response to oregovomab.